ENLV
Enlivex Therapeutics Ltd.
$0.95
-$0.01(-1.14%)
24
Overall
--
Value
25
Tech
23
Quality
Market Cap
$24.78M
Volume
784.03K
52W Range
$0.83 - $2.10
Target Price
$7.00
Company Overview
| Mkt Cap | $24.78M | Price | $0.95 |
| Volume | 784.03K | Change | -1.14% |
| P/E Ratio | -0.9 | Open | $1.00 |
| Revenue | -- | Prev Close | $0.96 |
| Net Income | $-29.1M | 52W Range | $0.83 - $2.10 |
| Div Yield | N/A | Target | $7.00 |
| Overall | 24 | Value | -- |
| Quality | 23 | Technical | 25 |
No chart data available
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest News
Enlivex Completes $212 Million Private Placement, Expands Digital Asset Strategy
TipRanks Auto-Generated Newsdesk•16 days ago
3 Penny Stocks to Watch Now, 11/25/25
Sheryl Sheth•17 days ago
Enlivex Reports Positive Six-Month Data for Knee Osteoarthritis Trial
TipRanks Auto-Generated Newsdesk•18 days ago
Enlivex Completes Private Placement to Fund Digital Asset Strategy
TipRanks Auto-Generated Newsdesk•18 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ENLV | $0.95 | -1.1% | 784.03K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enlivex Therapeutics Ltd. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW